Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying...
Transcript of Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying...
![Page 1: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/1.jpg)
Wang Chen, Amgen
PharmaSUG China 2017
![Page 2: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/2.jpg)
2
![Page 3: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/3.jpg)
3
Pharmacokinetics
Pharmacodynamics
![Page 4: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/4.jpg)
4
![Page 5: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/5.jpg)
5
![Page 6: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/6.jpg)
6
![Page 7: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/7.jpg)
7
![Page 8: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/8.jpg)
8
("pharmacokinetics"[Title/Abstract] OR "pharmacokinetic"[Title/Abstract] OR "PK" [Title/Abstract]) AND ("model"[Title/Abstract] OR "modeling"[Title/Abstract]) AND (Clinical Trial [ptyp] AND English [lang]) AND ("2007/08/20"[PDat]: "2014/08/20" [PDat])
![Page 9: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/9.jpg)
9
Problem: Most for description Limit use of safety evaluation
![Page 10: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/10.jpg)
10
![Page 11: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/11.jpg)
11
![Page 12: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/12.jpg)
Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between an instant concentration and its effect, but such data is difficult to observe for most drugs;
The current classification of PK-PD models is complicated which greatly enhanced the difficulties during the modeling process;
The design and specific research method of existing PK-PD studies also has some deficiencies which produces limits.
12
![Page 13: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/13.jpg)
13
![Page 14: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/14.jpg)
14
![Page 15: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/15.jpg)
15
Trial and data Modeling and simulationClassical PK-PD Model
suitable for data of instant concentration vs. its effect small sample size in trial a few doses design for trial time of sampling is limited with short space
modeling relationship between instant concentration and its effect which is difficult to observe for most drugs
with many concepts and hypothesizes which may be confused
a lot of time-consuming without covariates in the model
Mechanism PK-PD Model small sample size in trial time of sampling is limited with short space strictly designed to get necessary data of
intermediate products
highly effective in prediction with too much parameters which is complex and
hard to understand generally described by a flow chart a lot of time-consuming without covariates in the model
Parameterized PK-PD Model suitable for data of PK parameters vs. PD response large sample size in trial multiple-doses design for trial time of sampling is not limited
modeling the relationship between PK exposure and PD response which is much easier to observe
offering information which is at the heart of any determination of safety and effectiveness of drugs
relative easy in modeling with covariates in the model a widely use of population approach
![Page 16: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/16.jpg)
16
![Page 17: Wang Chen, Amgen - Pharmasug...Classical modeling method has some defects which limited the applying of PK-PD approach. Classical PK-PD modeling establishes the relationship between](https://reader036.fdocuments.net/reader036/viewer/2022071416/61131e18ad7f2205f45e6450/html5/thumbnails/17.jpg)
Name: Wang ChenOrganization: Amgen Asia R&DAddress: 13, Building , Jinchuang Building, 4560 Jinke RoadCity, State ZIP: Shanghai 01210 P. R. ChinaWork Phone: 189 1832 9098E-mail: [email protected]
17